About BRD4 Inhibitor-27
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo objectives ended up to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositi